Blood Tests Before Starting GLP-1s and Peptides

Why Baseline Labs Matter Before GLP-1s or Peptides

Baseline labs answer three simple questions: what is already abnormal, what could affect safety, and what can be compared later. That matters because GLP-1 receptor agonists and dual GLP-1/GIP agents sit inside a broader metabolic picture: glucose control, kidney function, liver enzymes, lipids, gallbladder risk, thyroid history, and current medications all change how a clinician thinks.

For research peptides beyond GLP-1s, the logic is similar but less standardized. There is no single "peptide blood panel" that applies to every compound. A conservative baseline usually starts with general health and clearance markers, then adds mechanism-specific tests. A GH-axis peptide is not monitored the same way as a metabolic GLP-1/GIP/glucagon research compound, and neither is monitored the same way as a short local-repair research peptide.

This article is educational, not a substitute for medical care. Prescription GLP-1 medications should be managed by a licensed clinician. Remy Peptides materials are for in-vitro laboratory research only and are not for human or veterinary use.

The Core Blood Test Checklist Doctors Commonly Start With

1. HbA1c: The Most Cited Single Test

If one blood test appears again and again in GLP-1 baseline discussions, it is HbA1c. AACE/ACE obesity guidance recommends screening people with overweight or obesity for prediabetes and type 2 diabetes using fasting glucose and A1C, alongside blood pressure, waist circumference, and lipid markers. Clinician-facing obesity pharmacotherapy references also place HbA1c in the baseline evaluation because glucose status changes how GLP-1 therapy is monitored.

HbA1c is useful because it is not just a one-moment glucose snapshot. It gives a longer view of glycemic exposure. For a clinician, that helps answer whether the person is in a normal, prediabetes, or diabetes range; whether hypoglycemia risk needs attention because of insulin or sulfonylurea use; and what number future labs should be compared against.

For research buyers evaluating metabolic peptides, HbA1c also prevents confusion later. If glucose markers improve or worsen after a protocol starts, the baseline tells you whether the change is new or was already present.

2. CMP: The Broad Safety Panel

The Comprehensive Metabolic Panel is often the most useful broad panel because it checks several systems at once. The kidney portion usually includes creatinine, estimated glomerular filtration rate (eGFR), and blood urea nitrogen (BUN). The liver portion includes ALT, AST, alkaline phosphatase, and bilirubin. The same panel also covers electrolytes such as sodium and potassium, plus glucose, calcium, albumin, and total protein.

Kidney markers matter because GLP-1 labels warn about acute kidney injury due to volume depletion, especially when nausea, vomiting, or diarrhea causes dehydration. A baseline creatinine and eGFR do not predict every problem, but they tell the clinician where the person started.

Liver enzymes matter because many people seeking metabolic therapy already have fatty liver or broader cardiometabolic risk. A baseline ALT or AST elevation may not block therapy, but it should be interpreted rather than ignored.

3. Lipid Panel: Cholesterol, Triglycerides, and Pancreatitis Context

A lipid panel usually includes total cholesterol, LDL-C, HDL-C, triglycerides, and often non-HDL cholesterol. AACE/ACE guidance specifically names the lipid panel when evaluating metabolic syndrome and dyslipidemia in people with overweight or obesity. Endocrine Society guidance also emphasizes lipid assessment in obesity and reassessment during pharmacologic weight-reduction therapy.

The most GLP-1-relevant subtest is often triglycerides. Very high triglycerides can increase pancreatitis risk, and pancreatitis is one of the adverse events clinicians are trained to watch for with GLP-1 receptor agonists. That does not mean a lipid panel predicts GLP-1 side effects. It means the panel helps map the background risk.

4. CBC With Differential: The General Health Snapshot

CBC stands for complete blood count. It includes red blood cells, white blood cells, hemoglobin, hematocrit, platelets, and often a white-cell differential. It is not GLP-1-specific, but it is useful as a baseline before many supervised peptide protocols because it can reveal anemia, infection/inflammation clues, platelet abnormalities, or an elevated hematocrit.

CBC becomes more relevant when a protocol overlaps with hormone optimization, GH-axis signaling, endurance/performance research, or symptoms such as fatigue. It also gives a simple "before" picture if later labs need interpretation.

5. Thyroid Screening: TSH First, History Always

Thyroid checks have two separate roles. First, TSH can help identify hypothyroidism or hyperthyroidism when symptoms, history, or unexplained weight changes make thyroid disease plausible. Second, GLP-1 labels carry warnings about thyroid C-cell tumors based on rodent findings and contraindications around personal or family history of medullary thyroid carcinoma or MEN2.

That does not mean everyone needs thyroid ultrasound or calcitonin testing before a GLP-1. The Wegovy and Zepbound labels both state that routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early MTC detection and may lead to unnecessary procedures because of low specificity and common background thyroid disease.

The practical version is simpler: check thyroid history carefully; use TSH when clinically indicated; escalate to free T4, free T3, antibodies, ultrasound, or endocrinology review only when the findings justify it.

6. Lipase and Amylase: Useful, But Easy to Misread

Lipase and amylase are pancreatic enzymes. Some clinicians include lipase before GLP-1 receptor agonists, especially when there is prior pancreatitis, gallbladder disease, severe abdominal symptoms, alcohol-related risk, or markedly high triglycerides. Obesity pharmacotherapy references commonly mention lipase in the GLP-1 baseline context.

The nuance is important: pancreatic enzyme elevations can happen without clinical pancreatitis, and large analyses have found that amylase/lipase elevations do not reliably predict acute pancreatitis. Cleveland Clinic's review notes that in major liraglutide data, lipase and amylase rose in some participants but had a positive predictive value for pancreatitis below 1%. For the broader adverse-event context, see the Ozempic vs Mounjaro vs Wegovy side-effects comparison.

So the question is not "can lipase ever move?" It is "does the person have symptoms or risk factors that make the result actionable?" Persistent severe abdominal pain, pain radiating to the back, vomiting, fever, or suspected gallbladder symptoms require medical evaluation. A silent, mildly abnormal enzyme result should not be interpreted in isolation.

7. Pregnancy, Medications, and History Are Part of the Baseline

Not every important check is a blood chemistry number. For people who can become pregnant, pregnancy testing is commonly relevant before GLP-1/GIP medications. The Zepbound label says to discontinue when pregnancy is recognized, and the Wegovy label warns that it may cause fetal harm when used for weight reduction or cardiovascular risk reduction.

Medication review is just as important. GLP-1 labels warn that hypoglycemia risk increases when combined with insulin or insulin secretagogues such as sulfonylureas. For tirzepatide, the label also advises special contraceptive handling because delayed gastric emptying can affect oral contraceptive exposure around initiation and dose escalation.

A good baseline review also asks about pancreatitis, gallstones, severe gastrointestinal disease, gastroparesis, diabetic retinopathy, kidney impairment, thyroid cancer history, MEN2, eating disorder history, alcohol use, and current supplements or compounds.

Peptide-Specific Add-Ons By Compound Category

"Peptides in general" is too broad for one universal lab list. The better approach is to start with the core baseline, then add tests that match the biology being studied.

Results That Should Make a Clinician Pause and Investigate

Baseline labs are not about passing or failing. They are about knowing what needs attention before a protocol starts. These are the patterns that usually deserve a clinician's interpretation:

• Diabetes-range HbA1c or very high fasting glucose: needs a glucose-management plan, especially if insulin or sulfonylureas are involved.
• Reduced eGFR or abnormal creatinine/BUN: important because dehydration from severe GI symptoms can stress kidney function.
• Elevated ALT/AST or bilirubin: may reflect fatty liver, medication effects, alcohol-related injury, viral hepatitis, or other causes that should not be guessed at.
• Very high triglycerides: raises pancreatitis-risk context and should be addressed directly.
• Abnormal TSH: thyroid dysfunction can alter weight, heart rate, energy, and temperature tolerance.
• High lipase with symptoms: abdominal pain plus enzyme elevation is different from an isolated mild lab abnormality.
• Positive pregnancy test: prescription GLP-1/GIP therapy and investigational peptide exposure need immediate clinician review.

When Are Labs Usually Repeated?

The common rhythm is baseline first, then a follow-up panel around 8 to 12 weeks or 3 months, then again around 6 months if the protocol continues. Obesity pharmacotherapy references describe repeating baseline-style labs at 3 and 6 months and then periodically after that. The exact schedule should match the compound, dose changes, symptoms, and the person's medical history.

Symptoms can move the schedule earlier. Severe nausea, vomiting, diarrhea, dehydration, abdominal pain, jaundice, fainting, persistent tachycardia, low blood sugar symptoms, or gallbladder-type pain are not "wait for the next lab date" situations.

Tests Not to Chase Without a Reason

More labs are not automatically better. Measuring natural GLP-1 or GIP hormone levels is usually not helpful in ordinary clinical practice because these hormones are short-lived and not how prescription response is typically monitored. Routine calcitonin or thyroid ultrasound for every GLP-1 user is also not supported by the FDA labels as a useful blanket screening strategy.

The best baseline is targeted, interpretable, and repeatable. A simple HbA1c plus CMP is often more useful than a large, expensive panel full of numbers nobody plans to act on.

A Simple Doctor Conversation Script

If you are speaking with a clinician about prescription GLP-1 therapy, a practical question is:

"Before starting, should we document HbA1c, fasting glucose, CMP, lipids, CBC, thyroid function if indicated, pregnancy status if relevant, and pancreatic/gallbladder risk factors? Are any of my current medications a hypoglycemia or absorption concern?"

If you are evaluating research peptides, the better question is:

"Which baseline markers match this compound's mechanism, and what would we repeat if something changes?"